Patients established on inhaler devices not on the formulary only to be switched to an alternative device if part of a formal clinical review
Anoro Ellipta® dry powder inhlaer (umeclidinium and vilaterol)
Duaklir Genuair® dry powder inhaler (aclidinium and formoterol)
Ultibro Breezhaler® dry powder inhlaer (glycopyronium and indacaterol)
Ipratropium with salbutamol nebules (Combivent®)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Specialist Prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
Treatment can be initiated in primary care after a recommendation from an appropriate specialist
Specialist initiation followed by maintenance prescribing in primary care
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation